vpc32183 and Glioma

vpc32183 has been researched along with Glioma* in 2 studies

Other Studies

2 other study(ies) available for vpc32183 and Glioma

ArticleYear
Lysophosphatidylserine induces calcium signaling through Ki16425/VPC32183-sensitive GPCR in bone marrow-derived mast cells and in C6 glioma and colon cancer cells.
    Archives of pharmacal research, 2008, Volume: 31, Issue:3

    Lysophosphatidylserine (LPS) can be generated following phosphatidylserine-specific phospholipase A2 activation. The effects of LPS on cellular activities and the identities of its target molecules, however, have not been fully elucidated. In this study, we observed that LPS stimulated intracellular calcium increased in mouse bone marrow-derived mast cells (BMMC), and rat C6 glioma and human HCT116 colon cancer cells and compared the LPS-induced Ca2+ increases with the response by lysophosphatidic acid (LPA), a structurally related bioactive lysolipid. In order to test involvement of signaling molecules in the LPS-induced Ca2+ signaling, we used pertussis toxin (PTX), U73122, and 2-APB, which are specific inhibitors for G proteins, phospholipase C (PLC), and IP3 receptors, respectively. The increases due to LPS and LPA were inhibited by PTX, U-73122 and 2-APB, suggesting that both lipids stimulate calcium signaling via G proteins (Gi/o types), PLC activation, and subsequent IP3 production, although the sensitivity to pharmacological inhibitors varied from complete inhibition to partial inhibition depending on cell type and lysolipid. Furthermore, we observed that Ki16425 completely inhibited an LPS-induced Ca2+ response in three cell types, but that the effect of VPC32183 varied from complete inhibition in BMMC and C6 glioma cells to partial inhibition in HCT116 cells. Therefore, we conclude that LPS increases [Ca2+]i through Ki16425/VPC32183-sensitive G protein-coupled receptors (GPCR), G protein, PLC, and IP3 in mouse BMMC, rat C6, and human HCT116 cells.

    Topics: Animals; Bone Marrow Cells; Calcium Signaling; Colonic Neoplasms; Dose-Response Relationship, Drug; Enzyme Inhibitors; Estrenes; Glioma; HCT116 Cells; Humans; Inositol 1,4,5-Trisphosphate Receptors; Isoxazoles; Lysophospholipids; Male; Mast Cells; Mice; Mice, Inbred BALB C; Organophosphates; Pertussis Toxin; Propionates; Pyridines; Pyrrolidinones; Rats; Receptors, Lysophosphatidic Acid; Time Factors; Type C Phospholipases

2008
Dioleoyl phosphatidic acid induces morphological changes through an endogenous LPA receptor in C6 glioma cells.
    Archives of pharmacal research, 2008, Volume: 31, Issue:5

    Previously, we suggested that dioleoyl phosphatidic acid (PA) and lysophosphatidic acid (LPA) increased [Ca(2+)](i) through endogenous LPA receptors coupled to pertussis toxin-sensitive G proteins in rat C6 glioma cells. In the present report, we investigated morphological changes and cytotoxicity induced by PA and LPA in C6 glioma cells. Isoproterenol treatment led to changes in the cell morphology of rat C6 glioma cells, which were reverted by the addition of PA and LPA. PA-and LPA-induced morphological reversions were inhibited by treatment with Ki16425, an LPA(1)/LPA(3) receptor antagonist. VPC32183, another LPA(1)/LPA(3) receptor antagonist with a different structure, only inhibited PA-induced morphological reversion but not LPA-induced reversion. However, the reversions were not inhibited by treatment with pertussis toxin, a specific inhibitor of G(i/o) proteins. In addition, cytotoxicity was only induced by LPA but not by PA in C6 glioma cells. Our results suggest that PA may act as a partial agonist at endogenous LPA receptors, which are sensitive to Ki16425 and coupled to PTX-insensitive G proteins, to evoke morphological changes in C6 glioma cells.

    Topics: Animals; Cell Line, Tumor; Cell Survival; Cytotoxins; Drug Partial Agonism; Glioma; Isoproterenol; Isoxazoles; Lysophospholipids; Organophosphates; Pertussis Toxin; Phosphatidic Acids; Propionates; Pyridines; Rats; Receptors, Lysophosphatidic Acid

2008